Numerous drug interactions related to radiopharmaceuticals take place every day in hospitals many of which are not reported or detected. Information concerning this kind of reaction is not abundant, and nuclear medicine staff are usually overwhelmed by this information. To better understand this type of reaction, and to help nuclear medicine staff deal with it, a review of the literature was conducted. The results show that almost all of radiopharmaceuticals marketed around the world present drug interactions with a large variety of compounds. This suggests that a logical framework to make decisions based on reviews incorporating adverse reactions must be created. The review also showed that researchers undertaking a review of literature, or even a systematic review that incorporates drug interactions, must understand the rationale for the suggested methods and be able to implement them in their review. Additionally, a global effort should be made to report as many cases of drug interaction with radiopharmaceuticals as possible. With this, a complete picture of drug interactions with radiopharmaceuticals can be drawn.
INTRODUCTION
According to Mather (2001) , radiopharmacy is scientifically recognized as an essential sub-specialty of nuclear medicine. Radiopharmaceuticals are used for two purposes; most importantly, is their use as diagnostic tools in clinical medicine. Radiopharmaceuticals also serve a purpose in research, both clinical and nonclinical, where they are used as tracers to observe or quantify biochemical or physiological processes (Tewson and Krohn 1998, Santos-Oliveira et al 2008) .
Radiopharmaceuticals have been in use for many years for diagnosis and therapy of a wide variety of diseases (Sampson, 2003) . In the early days of radiopharmacy, radiopharmaceuticals were generally prepared "in-house," and were not regarded as true medicines. In fact, they were, more often than not, prepared on the open bench where proper quality testing was not officially recognized.
There is a considerable body of evidence that biodistribution and pharmacokinetics of radiopharmaceuticals may be altered by a variety of drugs, disease conditions, and in some cases, surgical procedures (Hesslewood, Leung 1994) . Drs. Sampson and Hesslewood (1989) , state that these unknown and unrecognized interactions of radiopharmaceuticals with other compounds can lead to a state of total disorder.
Adverse drug reactions are a major cause of morbidity and mortality. In the United States, an estimated 701,547 people are seen every year at emergency departments due to adverse drug effects (Budnitz et al. 2006) . Adverse event reporting databases provide no valuable information on incidence, as some events may not be recognized, and in many countries reporting is not mandatory. Therefore, the total incidence of drug-radiopharmaceutical interactions is unknown Baranowska-Kortlylewicz, 2007) .
It is important to clarify the difference between drug interaction and adverse reaction. Ryan et al. (1996) defined adverse reaction to radiopharmaceuticals as any response to a drug which is noxious and unintended, occurring at doses used in man for prophylaxis, diagnosis, therapy of disease, or for modification of physiological function.
Drug interaction is defined by the Food and Drug Administration (FDA, 2009) as drug-drug interactions that can lead to changed systemic exposure, resulting in variations in drug response of the co-administered drugs. Therefore, it is important to evaluate potential drug interactions prior to market approval as well as during the postmarketing period, especially with regard to radiopharmaceuticals.
MATERIAL AND METHODS
The location and the selection of studies is one of the most important steps in a review of literature, and it is necessary to develop a literature search strategy based on key elements. The review question determines the nature of the search strategy. In this case our question was simple:
"Do radiopharmaceuticals present drug interactions?"
To address this question a review of the literature was conducted for drug interactions with radiopharmaceuticals. We searched computerized databases on radiopharmaceuticals including MEDLINE, EMBASE, the International Pharmaceutical Abstracts and Science Citation Index (published from 1920 to April 2007) using "radiopharmaceuticals / drug interactions," "radiopharmaceuticals / interactions," and several other search terms. This was supplemented with manual searches of major radiopharmacy textbooks. This review of the literature uses a selection of the material collected, and includes controlled trials, cohort studies, case-control studies and case series, in English, French, Deutsch and Portuguese languages. The difficulties in finding studies related to radiopharmaceutical drug interactions forced the acceptance of studies of lower quality. Each of the papers were retrieved and reviewed.
RESULTS AND DISCUSSION
The search strategy identified forty potentially relevant papers. Two reviews described more than ten related cases. Other authors published aspects of a single study in a number of related papers. Each of the publications included in this study was located through our search, and all met the inclusion criteria.
The results are shown in Table I , which summarizes all of the principal studies related to radiopharmaceuticals and adverse reaction. In addition, this table can be used as a guide for all nuclear medicine staff as it is portable and easy to follow. Narahara et al. (1989) β-blockers Thallous-201 Positive: reduce the uptake Sampson (1990) Heparinised catheter Technetium-pyrophosphate-99m Positive: reduce the uptake Lentle and Scott (1979) Heparinised catheter Technetium-pyrophosphate-99m Positive: reduce the uptake Chacko et al. (1977) Heparinised catheter Technetium-pyrophosphate-99m Positive: reduce the uptake Hegge et al. (1978) Heparinised catheter Technetium-pyrophosphate-99m Positive: reduce the uptake Estorch et al. (1990) Doxorubicin Antimyosin-indium-111 Positive: reduce the uptake Reuland et al. (1992) Doxorubicin Antimyosin-indium-111 Positive: reduce the uptake Pope and Bratke (1981) Opioid analgesics Technetium-iminodiacetic-99m Positive: reduce the uptake Feezer (1982) Phenobarbital and Bethanecol Positive: affect the kidney handling. Bobbinet et al. (1974) Aluminium (antacids) All radiopharmaceuticals Positive: reduce the uptake. Hesslewood and Leung (1994) Iodide pharmaceuticals
Iodide-131 and Iodide-123 Positive: reduce the uptake Sternthal et al. (1980) Perchlorate and pertechnetate ions
Iodide-sodium-131 Positive: reduce the uptake Dorr et al.(1993) Octreotide Indium-pentetreotide-111 Positive: reduce the uptake Sampson (1993) Cyclosphosphamide; vincristine and cisplatin Gallium-67 Positive: alters the pharmacokinetics Khafagi et al.(1989) Labetalol I-MIBG-131 Reduce uptake Gomes et al. (2001) Mitomycin C 99m Tc radiopharmaceuticals, 99m Tc-diethylenetriaminepentaacetic acid (99mTc-DTPA), 99mTc-dimercaptosuccinic acid (99mTc-DMSA), 99mTc-glucioheptonic acid (99mTc-GHA) 99mTc-DTPA: Increased the uptake in pancreas, ovary, uterus, stomach, kidney, spleen, thymus, heart, lung, liver, thyroid and bone. 99mTc-DMSA: Decreased the uptake in all organs except brain 99mTc-GHA Increased the uptake in liver and decreased in stomach, thymus, heart and thyroid.
Moreno et.al. (2007) Extract of Uncaria tomentosa
Radiobiocomplex sodium pertechnetate Increased uptake in pancreas and muscle Decreased the uptake in heart. Extract of Ginko biloba Sodium pertechnetate Decreased the uptake in duodenum Schroeder et al. (2007) Cigarette smoke Increased the uptake in lungs. 
CONCLUSION
The results showed that numerous drugs may interfere with radiopharmaceutical metabolism or biodistribution, and consequently, efforts must be made to minimize this type of event.
Our findings (Table I) can be particularly useful for the daily routine of nuclear medicine staff in hospitals where quick guides are always welcome.
In light of our results, drug interactions with radiopharmaceuticals should be better documented and reported. Efforts to increase adverse event reporting, and ideally consolidate reports worldwide, can provide a critically needed resource for prevention of drug-radiopharmaceuticals interactions.
